IRD vs TSHA
IRD: Clinical-stage biopharmaceutical company developing AAV-based gene therapies to restore vision in patients with inherited retinal diseases. TSHA: Taysha Gene Therapies is a clinical-stage biotech company pioneering AAV-based gene therapies to treat severe, rare monogenic diseases of the central nervous system, with a primary focus on Rett syndrome.
Side-by-side fundamentals
| Metric | IRD | TSHA | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $3.35 | $5.54 | |
| Market cap as of 2026-07-30 | $287M | $1.6B | |
| PEG as of 2026-07-30 | n/a | -1.25 | |
| Net margin as of 2026-07-30 | -892.4% | -780.3% | TSHA higher |
| Gross margin as of 2026-07-30 | +87.5% | n/a | |
| Operating margin as of 2026-07-30 | -359.1% | -782.5% | IRD higher |
| ROE as of 2026-07-30 | -316.4% | -56.1% | TSHA higher |
| ROA as of 2026-07-30 | -223.0% | -40.2% | TSHA higher |
| Debt / equity as of 2026-07-30 | 0.07 | 0.23 | IRD lower |
| Revenue growth (YoY) as of 2026-07-30 | -12.2% | +3.4% | TSHA higher |
| Revenue CAGR (3y) SEC XBRL | -29.1% | +57.5% | TSHA higher |
| Beta as of 2026-07-30 | 0.61 | 1.28 | |
| 1-year return as of 2026-07-27 close | +183.9% | +109.1% | IRD higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.